Dr. Schwartz has a broad background in cancer and neurodegenerative diseases biology. She has over 19 years of research experience in disease-related biomarkers. Dr. Schwartz is involved in discovering, developing, and commercializing novel therapeutic and diagnostic products for cancer and diseases of the central nervous system. She has many publications in peer-reviewed journals, including single-author major review papers. Prior to her employment at Ariadne-Dx, she worked at Ariadne Genomics where she was developed a diagnostics program. Also, Dr. Schwartz worked in 20/20 GeneSystems Inc., where she helped develop a diagnostic test for the early detection of lung cancer. She also previously worked at Panacea Pharmaceuticals Inc., where she was intensively involved in discovery and development work in regard to Alzheimer’s Disease and other neurodegenerative disorders.
Dr. Schwartz received her PhD in Cancer Biology at the Pasteur Institute, France and Institute of Biochemistry, Russia.